http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018045710-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe2d8a10ec14cd3998ef9c0637e811b1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2016-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_680751e4858d71e70148bcc5be913ef1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26942f893d6d8d8e4f9e3a9fd58621af |
| publicationDate | 2018-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2018045710-A1 |
| titleOfInvention | Use of eomesodermin to determine risk of allograft rejection |
| abstract | Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy. |
| priorityDate | 2015-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 351.